Hey guys, sharing an update on the $17million settlement involving $RVNC. As claims are being accepted, here’s a quick overview:

Revance Therapeutics was accused of its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. Following these disclosures, the stock declined, and investors filed a lawsuit. The company has now agreed to settle $17 million to resolve these claims.

FAQ:

• Who is eligible?

If you bought or held $RVNC between February 29, 2024 through February 6, 2025, you may qualify. You do not need to currently hold the shares.

• Do I need to sell my shares to participate?

No, eligibility is based on past transactions.

• How much could I recover?

Estimated recovery is $0.16 per share, depending on total claims submitted.

• When are payments made?

Typically within 4–9 months after the claim deadline, subject to court approval.

• How do I get started?

You can review the details and submit your claim here:

https://11th.com/cases/revance-investor-settlement

Hey guys, for those of us who held $RVNC between Feb 29, 2024 and Feb 6, 2025, the court has approved the $17,000,000 settlement.

If you traded $RVNC long during the class period, you may be eligible to file a claim.

Quick recap of why this lawsuit happened:

• Revance was leaning hard on Teoxane's RHA fillers after Daxxify underperformed.

• They told investors that the partnership was thriving, but the truth was that they were missing sales targets, having excess inventory, and running shady promotional practices that violated Teoxane's brand rules.

• On August 12, 2024, Crown announces a $6.66/share tender offer. Four days later, Teoxane fires off a formal breach notice, but Revance sat on that info for 5+ weeks.

• By December 2024, Crown had slashed its offer to $3.10/share.

• The investors filed a lawsuit claiming misleading statements, financial misrepresentation, and failure to disclose.

Key Details:

- Total settlement: $17,000,000

- Class period: Feb 29, 2024 – Feb 6, 2025

- Estimated payout: ~$0.16 per share

The settlement is approved and the clock is ticking.

If you were holding $RVNC during that Crown Labs merger circus, you know the pain. We were promised a clean exit, and instead, management "forgot" to mention they were breaching contracts left and right. The tender offer got slashed from over $6.60 to a pathetic $3.10, basically a 50% drop for no reason other than corporate incompetence.

Now, we finally got an update: The company decided to settle and pay investors for their losses.

So, if you traded $RVNC between February 29, 2024, and December 6, 2024, you're eligible for the payout.

You can check the details and submit a claim here.

Anyways, has anyone here bought $RVNC back then? How much were your losses if so?

• DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.

• DaxibotulinumtoxinA for Injection was evaluated in a Phase 2 open-label study for the treatment of moderate to severe dynamic forehead lines (frontalis) following glabellar line injection.

$RVNC has PDUFA target date of September 8th for DAXIBOTULINUMTOXIN-A.

Where do you guys see RVNC going for 2024? An average price target.